A comparative analysis of clinical outcomes in hematological patients afflicted with bacteremia attributable to carbapenem-resistant <i>Klebsiella pneumoniae</i> versus <i>Escherichia coli</i>.

Front Cell Infect Microbiol · 2025 · PMC12209189 · PMID 40599648

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Furthermore, among patients who received CAZ-AVI-based therapy within 72 hours, i.e., at an earlier stage, 30-day mortality rates tended to be lower, although this difference did not reach statistical significance ( Figure 2 ). 3.4.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

A comparative analysis of clinical outcomes in hematological patients afflicted with bacteremia attributable to carbapenem-resistant &lt;i&gt;Klebsiella pneumoniae&lt;/i&gt; versus &lt;i&gt;Escherichia coli&lt;/i&gt;.

The sentences

A comparative analysis of clinical outcomes in hematological patients afflicted with bacteremia attributable to carbapenem-resistant <i>Klebsiella pneumoniae</i> versus <i>Escherichia coli</i>.